Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewUCB 35625
说明： Potent CCR1 and CCR3 antagonist
化学名： 1,4-trans-1-(1-Cycloocten-1-ylmethyl)-4-[[(2,7-dichloro-9H-xanthen-9-yl)carbonyl]amino]-1-ethylpiperidinium iodide
纯度： ≥98% (HPLC)
生物活性 for UCB 35625
UCB 35625 is a potent chemokine CCR1 and CCR3 receptor antagonist. Inhibits MIP-1α-induced chemotaxis in CCR1 transfectants and eotaxin-induced chemotaxis in CCR3 transfectants (IC50 values are 9.57 and 93.8 nM respectively). Antagonizes CCR3-mediated entry of HIV-1 isolate 89.6 into NP-2 cells (IC50 = 57 nM).
Isomer also available.
化合物库 for UCB 35625
UCB 35625 is also offered as part of the Tocriscreen 2.0 Max and Tocriscreen Antiviral Library. 了解 Tocris 化合物库的更多信息。
技术数据 for UCB 35625
| 分子量 | 655.44 |
| 公式 | C30H37Cl2IN2O2 |
| 储存 | Store at +4°C |
| 纯度 | ≥98% (HPLC) |
| CAS Number | 202796-42-7 |
| PubChem ID | 6918496 |
| InChI Key | FOAFBMYSXIGAOX-LQGGPMKRSA-N |
| Smiles | ClC1=CC=C(OC(C=CC(Cl)=C3)=C3C2C(N[C@H]4CC[N@@+](C/C5=C/CCCCCC5)(CC)CC4)=O)C2=C1.ClC6=CC=C(OC(C=CC(Cl)=C8)=C8C7C(N[C@@H]9CC[N@+](C/C%10=C/CCCCCC%10)(CC)CC9)=O)C7=C6.[I-].[I-] |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for UCB 35625
| 溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
|---|---|---|---|
| 溶解性 | |||
| DMSO | 65.54 | 100 | |
| ethanol | 32.77 | 50 |
制备储备液 for UCB 35625
以下数据基于产品分子量 655.44。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| 浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.53 mL | 7.63 mL | 15.26 mL |
| 5 mM | 0.31 mL | 1.53 mL | 3.05 mL |
| 10 mM | 0.15 mL | 0.76 mL | 1.53 mL |
| 50 mM | 0.03 mL | 0.15 mL | 0.31 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
产品说明书 for UCB 35625
参考文献 for UCB 35625
参考文献是支持产品生物活性的出版物。
Sabroe et al (2000) A small molecule antagonist of chemokine receptors CCR1 and CCR3. J.Biol.Chem. 275 25985 PMID: 10854442
Lopes de Mendonca et al (2005) Site-directed mutagenesis of CC chemokine receptor 1 reveals the mechanism of action of UCB 35625, a small molecule chemokine receptor antagonist. J.Biol.Chem. 280 4808 PMID: 15548526
If you know of a relevant reference for UCB 35625, please let us know.
按产品操作查看相关产品
关键词: UCB 35625, UCB 35625 supplier, Potent, CCR1, CCR3, antagonists, Chemokine, Receptors, UCB35625, Rantes, CC, 2757, Tocris Bioscience
1 篇 UCB 35625 的引用文献
引用文献是使用了 Tocris 产品的出版物。 UCB 35625 的部分引用包括：
Liu et al (2016) Cancer-associated fibroblasts promote hepatocellular carcinoma metastasis through chemokine-activated hedgehog and TGF-β pathways. Cancer Lett. 379 49 PMID: 27216982
您是否知道使用了 Tocris UCB 35625 的优秀论文？ 请告知我们.
UCB 35625 的评论
目前没有该产品的评论。 Be the first to review UCB 35625 and earn rewards!
Have you used UCB 35625?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Rheumatoid Arthritis Poster
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.